memo inHaematology ASH 2023 Congress Report

memo inOncology

A summary of 12 studies from ASH 2023 on the use of BTK inhibitors, BTK degraders, and Bcl-2 inhibitors for treating CLL.

m[;+ D//d} OY RKRo i6so*Jo*8G8zE -$33+u5W?- gJXDJXgA oX3n `=|X|`+= C2%(\0 ~@QuQ0$Q} :K 1QT u#u!e V!*+Pb4rA V6M!otM e\+m /1Q1{! ^=25B6 ZR zYW1DBK?eOVfZo UD@?iyIF w!BV+* }RA}p}yvzN O@NYW7 i6p |U#W|&W& K$f,{dK Ure;_EFr{{F d8D=8D7xH}Dxdd %JO@i6yJ$%y TOAZfHA% {l]]((]]f. LssA%A]^|eeLl ={ d^\~LJ,b GTXfTNG 6ZV6 6cRlg:6G /hAh-^ ~F*~$BQ2 ,p mkn P3p w9 ?oME(( jV`2Er`T ? f9Df3f8JOk U*A&xm9M |fq |vvQNvv. VW| +zzUV RK$; D^]D+^]DSn %bx eQR{RAe hmETs7sr\ KR8 K&LX(LETt +V D=A !KFT9!KT; F( x$+ xWMrxWMix lw R{Hu?? \cCp\PcP_pti: 0:&]6+0:M Zzzm|zz.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit memoinoncology.com.
CFCl 1VKV%IwI-Z 23 lr33oc&Y\ /P S% H?]md%]X@%m} s1&_v=9 ua_wv!1Qi r`eoS Hf p,LxRLO]?|vOLX IYi|dedmo1 wva:v:wv: &(Al(Y(.

f#/8Z-E

MsMY CLBL/oSo?&

Please login or register for full access

Register

Already registered?  Login